AGO2 promotes telomerase activity and interaction between the telomerase components TERT and TERC by Laudadio, Ilaria et al.
 1 
(a) TITLE 
AGO2 promotes telomerase activity and interaction between the telomerase components TERT 
and TERC  
(b) authors’ full names 
Ilaria Laudadio1*, Francesca Orso2, Gianluca Azzalin1, Carlo Calabrò1, Francesco Berardinelli3, Elisa 
Coluzzi3, Silvia Gioiosa4, Daniela Taverna2, Antonella Sgura3, Claudia Carissimi1+ and Valerio 
Fulci1+ 
(c) affiliations 
1Dept. of Cellular Biotechnology and Hematology, “Sapienza” University of Rome, Italy; 
2Molecular Biotechnology Center, Dept. Molecular Biotechnology and Health Sciences, University 
of Turin, Italy 
3 Dept of Science, University of Rome "Roma Tre", Italy 
4 Istituto di Biomembrane, Bioenergetica e Biotecnologie Molecolari (IBIOM), CNR, Bari, Italy 
* corresponding author: Ilaria Laudadio ilaria.laudadio@uniroma1.it 
+ co-last authors 
(d) running head 
AGO and sRNA control telomerase activity  
(e) keywords 
Non-coding RNA, Argonaute, Telomerase, Telomere, Cancer 
 
 
 
 
 
  
 2 
ABSTRACT  
Telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) constitute the 
core telomerase enzyme that maintains the length of telomeres. Telomere maintenance is affected in 
a broad range of cancer and degenerative disorders. Taking advantage of gain and loss-of-function 
approaches, we show that ARGONAUTE2 (AGO2) controls telomerase activity and stimulates the 
association between TERT and TERC. AGO2 depletion results in shorter telomeres as well as in 
lower proliferation rate in vitro and in vivo. We also demonstrate that AGO2 interacts with TERC 
and with a newly identified sRNA (terc-sRNA), arising from the H/ACA box of TERC. Notably, 
terc-sRNA is sufficient to enhance telomerase activity when overexpressed.  Analysis of sRNA-Seq 
datasets shows that terc-sRNA is detected in primary human tissues and increases in tumors as 
compared to control tissues. Collectively, these data uncover a completely new layer of complexity 
in the regulation of telomerase activity by AGO2 and might lay the foundation for the exploitation of 
new therapeutic targets for tumors and telomere diseases. 
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INTRODUCTION 
Telomeres, the specialized nucleoprotein complexes present at the ends of linear eukaryotic 
chromosomes, play essential roles in maintaining genome stability and controlling cell proliferation. 
The length of human telomeric DNA is maintained by the addition of TTAGGG repeats to telomeres 
by a ribonucleoprotein (RNP) enzyme, telomerase. The catalytic components of the telomerase RNP 
are the telomerase reverse transcriptase (TERT) and the H/ACA box telomerase RNA (TERC), which 
is the template used for the synthesis of telomeres. TERT and TERC are necessary and sufficient for 
this reaction [1]. However in vivo, the telomerase holoenzyme also includes the accessory proteins 
dyskerin (DKC1), NOP10, NHP2 and GAR1 [2]. The formation of the catalytically active telomerase 
holoenzyme is a highly elaborate and multistep process of RNA maturation, assembly and trafficking 
within the nucleus [3].  
Most human somatic cells express insufficient or undetectable levels of telomerase; thus, telomeres 
shorten at each cell division, reaching a critical threshold, which triggers cellular senescence. On the 
contrary, continuously dividing cells such as germ cells, stem cells, and expanding lymphocytes 
require telomerase activity for maintaining telomere length and surviving. Deficiencies in telomerase 
activity, maturation, or recruitment to telomeres can lead to human telomeropathies, such as aplastic 
anemia and dyskeratosis congenita [4]. On the other hand, telomerase activity is highly elevated in 
85%–90% of human cancers and in over 70% of immortalized human cell lines [5][6], suggesting 
that the activation of telomerase is crucial for continued cell proliferation. Hence, greater knowledge 
of telomerase biology and regulation is required to increase our understanding of both human diseases 
and natural cellular processes.  
Argonaute (AGO) proteins are small RNA (sRNA)-binding proteins which use the sequence 
information encoded in the sRNA as a guide to identify complementary target RNAs. Humans have 
four AGO proteins, AGO1, AGO2, AGO3 and AGO4, sharing about 80% identity in their amino acid 
sequences [7]. Among them, only AGO2 has retained the ability to cleave target RNAs [8]. The most 
studied function of AGO proteins is post-transcriptional gene silencing in association with 
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microRNAs. However in the last years, sRNA profiling by next-generation sequencing (sRNA-Seq) 
allowed the identification of novel classes of sRNAs bound to AGO proteins in mammalian cells, in 
addition to miRNAs [9] [10] [11] [12]. Moreover, recent evidences involve AGO proteins in nuclear 
processes such as transcriptional gene silencing [13][14], DNA damage [15], chromatin remodeling 
[9] and splicing [16][17]. These new data strongly suggest that AGO proteins can exert previously 
unexpected functions. 
Here, we identify a new function of AGO2 in human telomerase biology. Modulation of AGO2 
expression by loss- and gain-of-function approaches results in changes in telomerase activity.  Taking 
advantage of an AGO2 knock-out (KO) human cell line, we demonstrate that AGO2 controls the 
association between TERT and TERC and this results in telomere shortening, lower proliferation rate 
in vitro and tumor growth in vivo. We further discover a new AGO2-bound sRNA, herein referred to 
as terc-sRNA, which arises from the H/ACA domain of TERC. Terc-sRNA is detected not only in 
human cell lines but also in primary human tissue and its expression increases in tumor samples as 
compared to non-tumor tissues. Interestingly, overexpression of terc-sRNA is sufficient to increase 
telomerase activity. Together, these data show that AGO2 and the newly identified terc-sRNA are 
novel players in human telomerase regulation.  
 
RESULTS 
Proliferation and tumor growth are affected by AGO2 depletion. 
AGO2 encodes for the only member of the AGO protein family that retains endonucleolytic activity 
in human cells [8]. While the roles of AGO2 in miRNA mediated post-transcriptional regulation and 
RNAi have been thoroughly characterized, the roles of AGO2 in the nucleus of human cells, including 
a role in DNA damage [15], chromatin remodeling [9] and splicing [16], are currently beginning to 
be elucidated. Because of these unexpected functions of human AGO2, an experimental tool to 
evaluate AGO2 novel functions in human cell biology is required. Therefore, we took advantage of 
genome editing to generate inactivating mutations in all three copies of the AGO2 locus present in 
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the human cell line HeLaS3 by using Zinc Finger Nucleases (AGO2KO cells) [18].  
Firstly, we investigated how AGO2 depletion might influence cell proliferation and survival. 
Comparison of growth curves of parental and AGO2KO HeLaS3 cells highlighted that the absence 
of AGO2 impaired the proliferative capacity of HeLaS3 cells (Fig 1A). Similarly, the results of 
colony formation assay also showed that clonogenic survival was decreased in AGO2KO cells as 
compared to HeLaS3 (Fig 1B). We also assessed in vivo proliferation of AGO2KO cells by injecting 
subcutaneously immunocompromised mice with parental HeLaS3 and AGO2KO cells. In line with 
in vitro assays, when we measured tumors diameter at different time points (Fig 1C) and tumor weight 
at 30 days post-injection (Fig 1D), we found that AGO2 depletion inhibits the growth of HeLaS3 
xenografts in nude mice. 
Next, we profiled the transcriptome of HeLaS3 and AGO2KO cells by microarray. Microarray 
analysis showed that only 12 genes are differentially expressed in AGO2KO compared to wild-type 
cells (FDR < 0.01) (Appendix figure S1). Since the endpoint of the microRNA pathway is mRNA 
degradation, these data suggest that AGO2 is unlikely to control proliferation in human cells via 
miRNA-mediated regulation of gene expression [19], suggesting the existence of an alternative 
mechanism.  
AGO2 interacts with a sRNA arising from TERC locus (terc-sRNA)  
Several recent papers show that AGO proteins interact with small RNAs other than miRNAs, 
displaying novel roles in particular in the nuclear compartment [15][16][17][14][9]. We recently 
published that in the nuclei of human cells AGO2 is bound to sRNAs arising from transcriptional 
termination sites (TTSa-RNAs). We found that AGO2-bound TTSa-RNAs derive from genes 
involved in cell cycle progression regulation [18]. In HeLaS3 and HCT116 cell lines nuclear AGO2 
interacts with a 23 nt-sRNA arising from TTS of the telomerase RNA component TERC (positions 
425 to 447), herein referred to as terc-sRNA (Fig 2A). Based on its association with AGO2, its 
specific size and the fact that almost no reads map on TERC RNA outside positions 425 – 447 (Fig 
EV 1A), we conclude that terc-sRNA is not a mere by-product of TERC degradation, but it is a 
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specific, biologically-generated sRNA. We further confirmed that TERC is the precursor of terc-
sRNA by stably overexpressing TERC in HeLaS3 cells by lentiviral transduction (Fig 2B). Indeed, 
we found higher levels of terc-sRNA in sRNA fraction (< 100nt) of TERC-overexpressing cells than 
in control cells (Fig 2C), as assessed by RT-qPCR using specific primers [20] (Appendix Figure 2A-
C). 
 In human cells, impairment of core components of telomerase RNP, TERC and TERT, not only 
determines short telomeres, but also affects proliferation and colony forming efficiency, mimicking 
the phenotype we observed in AGO2KO cells [21][22]. As a consequence, we hypothesized that 
AGO2 and terc-sRNA might be involved in telomerase-mediated telomere lengthening. 
 
AGO2 controls telomere lengthening and enhances telomerase activity.  
To verify this hypothesis, we compared relative telomere length in parental and AGO2KO HeLaS3 
by quantitative PCR [23]. The ratio of the copy number of telomeric repeats (T) and the copy number 
of a reference gene was calculated. As a reference, we used multicopy genes, with thousands of copies 
throughout the genome, similar to telomeres (Alu in Fig 3A and 18S in Appendix figure S3A), as well 
as 36B4 (Appendix figure S3A), which is a four-copy gene in HeLaS3 cells. Regardless to the 
reference we used, average telomere length in AGO2KO cells was 70% shorter than parental cells.  
In order to further confirm the observed telomere shortening and analyze single telomere length 
distributions in AGO2KO and HeLaS3 cells, centromere-calibrated telomeric QFISH was performed 
(Fig 3B). Histograms of telomere length frequencies showed a proportion of short telomeres much 
higher in AGO2KO cells than in control cells (Fig 3C) and the difference in telomere length was 
extremely significant and affected both q and p arms (Fig 3C and Appendix figure S3B). In particular, 
comparing the percentage of telomeres shorter than 3 arbitrarily chosen thresholds (i.e. 5, 10 and 15 
T/C%), we always found a very significantly higher proportion of eroded telomeres in AGO2KO 
cells than in HeLaS3 cells (Appendix figure S3C).  
Notably, when we measured telomerase activity via Telomerase Repeated Amplification Protocol 
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(TRAP) [24], we observed a decreased telomerase activity in AGO2KO cells as compared to parental 
cells (Fig 3D, E). Coherently, this phenotype was partially rescued by stable overexpression of 
FLAG/HA-tagged AGO2 (FH AGO2) in AGO2KO cells (Fig 3F, Appendix figure S3D). To further 
confirm that AGO2 expression can modulate telomerase activity, we stably overexpressed FH AGO2 
in HeLaS3 parental cells (HeLaS3_FH AGO2; Appendix figure S3E) and we performed analysis of 
telomerase activity (Fig 3 G). In line with the results obtained in AGO2KO cells, overexpression of 
AGO2 was sufficient to enhance telomerase activity as compared to control cells. These data show 
that AGO2 controls telomere elongation capacity and telomerase activity in human cells, pointing out 
AGO2 as a new player in telomere lengthening.  
 
AGO2 affects the association between TERT and TERC  
We next focused our attention on the mechanism by which AGO2 controls telomerase activity. We 
hypothesized that AGO2 might directly or indirectly control expression levels of TERT and /or 
TERC. However, neither TERC RNA levels (Fig 4A), nor TERT protein levels (Fig 4D, E) were 
affected by AGO2 depletion.  
Furthermore, it has been reported that 3’-extended or polyadenylated isoforms of TERC are post-
transcriptionally processed in order to give rise to mature non-polyadenylated 451 nt-long TERC and 
that this processing is required for telomere maintenance [25][26]. We therefore checked if AGO2 
regulates telomerase activity  by controlling TERC maturation. We quantified 3’-extended and oligo-
adenylated TERC by random hexamer- and oligo d(T)-primed qRT-PCR respectively, but we did not 
detect any change in the abundance of immature forms of TERC when AGO2 is ablated (Fig 4B, C). 
Finally, we aimed to study if the assembly of the core components of telomerase RNPs, namely TERC 
and TERT, was affected in AGO2KO cells. By RIP, we looked at endogenous TERC-TERT 
interaction in both parental and AGO2KO HeLaS3 cells. Notably, we found that enrichment of TERC 
in TERT-IPed RNA is impaired in AGO2KO cells, as compared to parental HeLaS3 (Fig 4F). As a 
negative control, we analyzed HOTAIR, which is not enriched in TERT-IP as compared to mock IP 
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(IgG). No variation in HOTAIR enrichment in TERT-IP samples can be detected between AGO2KO 
and parental HeLaS3. Coherently, re-expression of AGO2 in AGO2KO cells (AGO2KO_FH AGO2) 
increased association between TERT and TERC as compared to AGO2KO control cells 
(AGO2KO_GFP; Fig 4G). Importantly no protein-protein interaction between AGO2 and TERT 
could be detected by co-immunoprecipitation assay (Fig 4H), suggesting that AGO2 is not part of 
telomerase RNPs.  
Overall, our data indicate that AGO2 regulates telomerase activity through the control of TERT 
association with TERC in the assembly of active telomerase RNP.  
 
AGO2 is recruited on TERC.  
Since AGO2 is an RNA binding protein we checked for interaction between AGO2 and TERC RNA. 
We firstly performed RIP with an antibody against AGO2 from HeLaS3 cells and we found an 
enrichment of TERC RNA in AGO2-IP as compared to IgG, as assessed by RT-qPCR (Fig 5A). 
Association between AGO2 and TERC was further verified by immunoprecipitating FH AGO2 from 
HeLaS3_FH AGO2 and HeLaS3_GFP cells (as a negative control) with an HA antibody (Fig 5B).  
We additionally demonstrated the interaction between AGO2 and TERC by taking advantage of 
HeLaS3 cells stably overexpressing TERC (Fig 2B). Ectopically expressed TERC RNA (ectoTERC) 
can be discriminated by RTqPCR from the endogenously expressed one, because it is transcribed 
from the integrated lentiviral vector as a longer RNA tagged with a specific sequence downstream 
the 3’end of TERC coding region. Indeed, using specific primers, ectoTERC RNA was detected only 
in HeLaS3_TERC but not in control HeLaS3 cells (HeLaS3_GFP) (Appendix figure S4A). We 
immunoprecipitated AGO2 and we found that it is also bound to the ectopically expressed TERC 
RNA (Appendix figure S4B). 
Through base pairing, AGO2-loaded sRNAs recognize complementary RNAs as their targets. Terc-
sRNA arises from the right arm of the terminal hairpin of TERC, displaying a good complementarity 
to the left arm of this hairpin. Therefore, we looked for putative target sites of terc-sRNA in TERC 
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RNA by using the RNA-hybrid program, which finds the energetically most favorable hybridization 
sites of a sRNA in a large RNA [27]. Surprisingly, the two-best pairing between TERC and terc-
sRNA involved positions 313-340 of TERC, in the conserved region 4 (CR4)/CR5 domain of TERC 
(minimum free energy: -30 Kcal/mol) and positions 12-31 of TERC, localized in the template 
boundary element (TBE) at the 5’end of TERC (minimum free energy: -29.4 Kcal/mol) (Appendix 
figure S4C-D).  
These data suggest that terc-sRNA not only originates from TERC RNA, but might also target TERC 
RNA in two different binding sites, guiding interaction between AGO2 and TERC by base pairing.  
Finally, in order to verify whether the interaction between AGO2 and TERC is mediated by terc-
sRNA predicted sites, we destroyed complementarity by mutating TERC sequence in positions 313-
340 and by deleting TERC positions 12-31 in the lentiviral vector coding for ectoTERC (TERC(313-
340mut) and TERC (Δ 12-31), respectively). HeLaS3 cell were transduced with mutated TERC- 
coding lentiviral particles (HeLaS3_TERC(313-340mut) and HeLaS3_TERC (Δ 12-31)). The 
expression levels of ectoTERC were comparable in HeLaS3_TERCwt, HeLaS3_TERC(313-340mut) 
and HeLaS3_TERC (Δ 12-31) (Appendix figure S4E). We next checked association between AGO2 
and ectoTERC, by immunoprecipitating AGO2-associated RNA from lysates of cells expressing the 
different TERC variants. As shown in Fig 5C, when we compared ectoTERC-AGO2 binding in 
HeLaS3_TERCwt, HeLaS3_TERC(313-340mut) and HeLaS3_TERC (Δ 12-31), we found that 
enrichment of ectoTERC in RIP AGO2 samples decreases when terc-sRNA binding sites are mutated. 
Overall, these data demonstrate that AGO2 binds to TERC. Moreover, positions 313-340 and 12-31 
of TERC, displaying base-complementarity with terc-sRNA, are required for this interaction, 
strongly suggesting that terc-sRNA guides AGO2 onto TERC.   
 
Terc-sRNA biogenesis does not involve DICER or AGO2. 
By sRNA-Seq, we showed that AGO2 binds to terc-sRNA (Fig EV1A). To confirm this interaction, 
we immunoprecipitated endogenous AGO2 in HeLaS3 whole-cell extract and we amplified terc-
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sRNA by qRT-PCR (Fig EV1B-C). In line with high-throughput data, terc-sRNA is enriched in 
AGO2-IP sample as compared to mock IP, performed using matched immunoglobulin.  
Terc-sRNA derives from a stem-loop structure (Fig 2A), reminiscent of miRNA precursors. We 
hypothesized that DICER or AGO2, both of which are known to control miRNA processing and 
stability [28], could be involved in terc-sRNA biogenesis. To answer this question, we compared 
terc-sRNA abundance by RT-qPCR in the sRNA fraction isolated from HCT116 and HCT116 
DicerEX5 (a subclone of HCT116 cells in which DICER has been impaired) [29] and from parental 
and AGO2KO HeLaS3 cell lines (Appendix figure S2D-E, Fig EV1D-F). Impairment of DICER or 
AGO2 catalytic activity did not determine any changes in terc-sRNA levels. On the contrary, miRNA 
expression is downregulated in HCT116 DicerEX5 and AGO2KO HeLaS3 cells as compared to 
matched wild-type cells (Fig EV1E and G). We concluded that terc-sRNA can be processed 
independently of DICER and AGO2. In agreement with these observations, we could not find any 
evidence for a small RNA duplex as a precursor of terc-sRNA processing. Indeed, neither reads 
arising from the complementary 5’ strand of the stem-loop structure nor reads arising from antisense 
transcription can be detected (Appendix figure S5). 
 
Terc-sRNA overexpression increases telomerase activity. 
We next investigated whether modulation of terc-sRNA levels can control human telomerase activity. 
We overexpressed terc-sRNA in parental HeLaS3 cells through transient transfection of a synthetic 
terc-sRNA or a control siRNA (ctl-siRNA) and checked telomerase activity via TRAP assay. As 
shown in Fig 6A-B, terc-sRNA transfected HeLaS3 cells displayed higher telomerase activity as 
compared to ctl-siRNA transfected cells, mimicking the effect of AGO2 overexpression (Fig 3G) and 
suggesting that the role of AGO2 in telomere biology might be, at least in part, mediated by terc-
sRNA.  
Furthermore, in order to study if stimulation of telomerase activity by terc-sRNA requires AGO2, we 
overexpressed synthetic terc-sRNA or ctl-siRNA in AGO2KO cells (Fig 6A-B). Surprisingly, in 
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AGO2KO cells terc-sRNA overexpression was sufficient to recover telomerase activity deficit 
caused by AGO2 depletion. These data unravel that abundance of terc-sRNA modulates telomerase 
activity in human cells, and that activity of terc-sRNA is not strictly dependent upon AGO2 
expression.  
Therefore, we postulated that not only AGO2 but also other AGO proteins might bind terc-sRNA, 
and TERC and participate in telomerase biology. Indeed, AGO members are mainly considered to be 
functionally redundant as far as loading of sRNAs, such as miRNAs, is concerned [30][31][32]. We 
focused our attention on AGO1, which is the second most abundant AGO protein in HeLaS3, behind 
AGO2 [33]. We reanalyzed data of sRNA-seq that we previously obtained from immunoprecipitation 
of AGO1 from nuclei of HeLaS3 [9], looking for sRNAs mapping on TERC locus. AGO1 binds a 
sRNA deriving from TERC 3’end and corresponding to terc-sRNA (Fig EV2A). We validated this 
interaction by immunoprecipitating endogenous AGO1 from HeLaS3 whole-cell extract, and by RT-
qPCR we demonstrated that both terc-sRNA and TERC are enriched in AGO1-IP RNA as compared 
to mock IP-RNA (IgG) (Fig EV2B-D). This evidence suggests that also AGO1 might be involved in 
the control of telomerase activity. To answer this question, we genetically inactivated AGO1 loci in 
both parental HeLaS3 and AGO2KO cells by CRISPR/Cas9. We generated two independent 
AGO1KO and two AGO1/AGO2 double KO (AGO1/AGO2dKO) monoclonal cell lines (Appendix 
figure S6A). As controls, we isolated subclones from parental HeLaS3 and AGO2KO cells following 
transduction with CRISPR/Cas9 control vector (HeLaS3 WT CRISPR neg and AGO2KO CRISPR 
neg). We analyzed telomerase activity by TRAP and we could not detect any difference between 
AGO1KO and HeLaS3 WT CRISPR neg cells. Moreover, telomerase activity of AGO1/AGO2dKO 
cells is comparable to what observed in AGO2KO CRISPR neg cells (Fig EV2E, Appendix figure 
S6B). In conclusion, AGO1 depletion does not impact telomerase activity neither in wild type nor in 
AGO2KO background, suggesting that AGO2 is the major player of this new mechanism. Otherwise 
under extreme conditions, such as overexpression of terc-sRNA, also AGO1 might mediate the 
activity of this sRNA. 
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Terc-sRNA is detected in primary human samples and is overexpressed in tumor tissues  
 
Finally, we asked if terc-sRNA can be detected in primary human tissues. We looked for publicly 
available datasets in which microRNA profile was assessed by NGS, and we identified five datasets 
containing sRNA expression profiles in tumor samples and control tissues (normal, adjacent or benign 
tumors). In all datasets analyzed, we could detect terc-sRNA expression (Fig EV3A) in both tumor 
samples and control tissues, thus confirming that this small RNA is expressed in primary human 
tissues.  
Moreover, given that de-regulation of other sRNA classes has been reported in human tumors 
[34][35], and that in vitro overexpression of terc-sRNA increases telomerase activity, thus possibly 
conferring a selective advantage to cells over-expressing this sRNA (Fig 6), we also compared terc-
sRNA abundance in tumor samples and control tissues. Interestingly, we highlighted that terc-sRNA 
is significantly overexpressed in breast cancer and in lung adenocarcinoma as compared to normal 
tissues. In adrenocortical tumors, we found a significant increase of terc-sRNA in carcinoma as 
compared to adenoma. The lack of statistical significance of the result obtained in endometrial cancer 
dataset is likely due to the small number of samples in this dataset (n=6) (Fig EV3B). Notably, due 
to lack of matched long non-coding RNA expression data, we could not quantify TERC expression 
in the same samples, hence we cannot rule out the possibility that terc-sRNA overexpression in tumor 
samples is due to TERC over-expression in the same samples.  
DISCUSSION 
 
Telomerase activity is undetectable in most human somatic cells. Thus, telomere length decreases 
across each cycle of cell division and when telomeres reach a critically short length, cell senescence 
is induced. However, certain human cell populations such as germ cells, stem cells, and expanding 
lymphocytes, express telomerase, and thereby, maintain telomere length and escape from cellular 
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senescence. Defects in genes involved in telomerase biology affect the renewal of critical stem cell 
populations, particularly in highly proliferative tissues, and cause a spectrum of disorders referred to 
as telomeropathies [36]. On the other hand, improper activation of telomerase in somatic cells 
contributes to tumorigenesis because it enables neoplastic cells to proliferate indefinitely. Indeed, 
reactivation of TERT expression is a hallmark of carcinogenesis and is seen in more than 80%–90% 
of tumors [37]. Thus, deeper characterization of telomerase regulation is attractive for the 
development of novel therapeutic targets and biomarkers in a wide range of pathologies.  
Here, we describe a new and unanticipated role for AGO2 in controlling human telomerase activity 
through the regulation of association between the telomerase core components, TERT and TERC. 
Furthermore, we identified terc-sRNA as a novel AGO-associated sRNA arising from the right arm 
of the terminal hairpin of the H/ACA box of TERC and whose over-expression promotes telomerase 
activity in human cells.  
In mammalian cells, there are 4 AGO proteins (AGO1–4) which are key components of miRNA-
mediated post-transcriptional modulation of gene expression.  We show that depletion of AGO2 by 
genome editing in the human cell line HeLaS3 determines impaired proliferation and colony forming 
efficiency as well as telomere shortening and decreased telomerase activity, a phenotype reminiscent 
of those caused by telomerase core components (TERC and TERT) decrease. These effects of AGO2 
ablation might be the results of an impairment in miRNA function.  Indeed, the absence of AGO2 
could deregulate the expression of genes involved in telomerase biology. However, when we profiled 
transcriptome of HeLaS3 and AGO2KO cells by microarray, only 12 genes were deregulated in 
AGO2KO cells (FDR< 0.01), suggesting that AGO1/3/4 might mostly compensate lack of AGO2 as 
far as loading of miRNA is concerned [38][31]. Importantly among differentially expressed genes, 
no gene directly involved in telomerase biology can be found. Coherently, TERC RNA and TERT 
protein levels are not affected by AGO2 depletion. These data suggest that AGO2 is unlikely to 
control telomere lengthening via deregulation of gene expression, but probably through alternative 
mechanisms.  
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Interestingly we showed that AGO2 as novel TERC-binding protein. While impairment  of previously 
described TERC binding proteins, such as DKC1 [39], NOP10 [40], NHP2 [41], NAF1[42]  and 
FXR1 [43], cause defects in telomere maintenance by  affecting TERC stability, we show that AGO-
TERC interaction is unlikely to control TERC abundance. Moreover, this interaction is impaired by 
mutations of TERC sequence in positions 313-340 in CR4/CR5 domain. Interestingly, in human cells 
depletion of TERC residues 225-348 [44] and a mutation of TERC (G319A) [45] do not alter TERC 
overall levels but compromise telomerase function by decreasing binding of TERC to TERT in vitro 
and in vivo. Since AGO2 depletion affects the association between TERC and TERT, we speculate 
that AGO-TERC interaction might stimulate assembly of active telomerase RNPs. An intriguing 
possibility is that binding of AGO to TERC might drive TERC folding. This hypothesis would 
recapitulate what previously described in ciliate telomerase biogenesis. In Tetrahymena thermophile, 
interaction between the  stem terminus element of  telomerase RNA (corresponding to CR4/CR5 
domain in vertebrates) and a La-motif RNA binding protein induces structural rearrangement of 
telomerase RNA, which in turn promotes the binding of TERT  to form the functional telomerase 
complex [46]. Interestingly, reconstitution in vitro of human telomerase is highly dependent on the 
folding state of TERC, suggesting that TERC folding is a limiting factor in vertebrate telomerase 
assembly as well [47][48].  
Terc-sRNA is predicted to target sequences in CR4/CR5 (positions 313-340) and in the TBE domains 
(positions 12-31) of TERC. The integrity of these predicted binding sites on TERC is required for 
AGO2 binding to TERC, strongly suggesting that terc-sRNA drives AGO2 onto its target TERC via 
base-complementarity. Moreover, terc-sRNA overexpression results in higher telomerase activity, 
mimicking the effect of AGO2 overexpression. A possible explanation for this data is that terc-sRNA 
recognizes TERC and recruits AGO2 and additional still-unknown factors to TERC RNA, driving 
AGO2 effects on TERC-TERT association. Although our experimental observations demonstrate a 
role for terc-sRNA in telomerase biology, a conclusive evidence that AGO2/terc-sRNA/TERC 
complexes mediate AGO2-dependent stimulation of telomerase activity is still lacking.  Indeed, since 
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terc-sRNA and TERC share the same sequence and arise from the same locus, any terc-sRNA loo-
of-function approach either via antisense oligonucleotides or genome-editing will target both terc-
sRNA and TERC, making any interpretation of this manipulation misleading.  Therefore, further 
efforts are required to disclose if AGO/terc-sRNA complexes are required to control telomerase 
activity and to explore the hypothesis that other still-unidentified sRNAs (miRNAs or others) could 
cooperate with AGO2 in this process. 
Notably, we show that terc-sRNA is expressed in primary human tissues. Furthermore, terc-sRNA is  
overexpressed in different cancers. Several expression studies have found that also AGO2 is highly 
expressed in different kinds of tumors such as breast cancer, high-risk myeloma, colon cancer, liver 
cancer, and gastric carcinoma[49]. Since our results demonstrate that AGO2 and terc-sRNA are able 
to modulate telomerase activity in human cell lines, we speculate that concomitantly reactivation of 
TERT expression and overexpression of AGO2 and/or terc-sRNA might confer a selective advantage 
to tumor cells and probably a more aggressive phenotype. However, lack of information on TERC 
expression in the datasets we analyzed does not allow us to assess whether the observed terc-sRNA 
over-expression is a consequence of TERC over-expression. Therefore, we believe that further 
investigation will be required to unravel the relationship between TERC and terc-sRNA in primary 
human tissues as well as to validate of terc-sRNA and AGO proteins as valid biomarkers for diagnosis 
or prognosis of human malignancies. 
Finally, it was shown that several mutations correlated to dyskeratosis congenita reduce but do not 
abolish TERC expression ([50] [51] [25] [40] [41]). Therefore, modulation of AGO or terc-sRNA 
levels might enhance the interaction between TERT and residual TERC and partially counteract 
telomere shortening in patients affected by this degenerative disorder.  
Overall, insights from this work might be the starting point for future investigation of AGO proteins 
and terc-sRNA as biomarkers and/or therapeutic targets to modulate telomerase activity and self-
renewal in tumors and telomeropathies. 
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MATERIALS AND METHODS 
Cell culture and transfection  
Parental and AGO2KO [18] HeLaS3 cells were grown in DMEM medium supplemented with 10% 
(v/v) fetal bovine serum, 2mM L-Glutamine and Penicillin-Streptomycin. HCT116 and HCT116 
DICEREx5 cells [29] were grown in McCoy’s 5A medium supplemented with 10% (v/v) fetal bovine 
serum, 2mM L-Glutamine and Penicillin-Streptomycin. AGO1KO and AGO1/AGO2dKO 
monoclonal cell lines were obtained by using CRISPR/Cas9 technology. HeLaS3 and AGO2KO cells 
were transduced with a lentiviral vector (LentiAGO1CRISPR v2, GeneScript) coding for a gRNA 
sequence targeting AGO1 (TCAGCGCGTTCGCTTCACCA) or an empty vector (LentiCRISPR v2, 
a gift from Feng Zhang, Addgene plasmid # 52961 [52]) as a control. Transduced cells were selected 
by puromycin for 2 days. Individual clones were isolated by serial dilution and assayed by Western 
Blot for AGO1 expression. KO of all AGO1 alleles was confirmed by Sanger sequencing. 
Overexpression of terc-sRNA was performed by transfecting 20 nM siRNAs (terc-sRNA: 
UGCACCCAGGACUCGGCUCACA(Sigma);ctl-siRNA: GCUUCAUAAGGCGCAUGC[dT][dT]) 
for 4 days using INTERFERin®, according to the manufacturer's instructions (Polyplus 
Transfection).  
Cell proliferation assays 
For cell proliferation curves, 8x104 cells were seeded in 12-well plate. Cells were counted every 24h 
for 5 days using EVE™ Automated Cell Counter, (NanoEnTek). For the colony-formation assay, 500 
cells were placed into each well of a six-well plate and maintained in media containing 10% FBS for 
11 days, replacing the medium every 4 days. Colonies were fixed and stained with crystal violet 
(0.5%w/v) in 20% methanol for 30min, plate was washed in PBS, and counted using a microscope.  
In vivo tumor growth  
All experiments performed with live animals complied with ethical care. 5 × 106 parental or  
AGO2KO HeLaS3 cells  (in PBS) were subcutaneously injected into the flanks of 8- to 12-week-old 
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NOD/SCID/IL2R_null (NSG) immunocompromised mice and tumor diameters were measured twice 
a week. Tumors were harvested 30 days following injection and weighted.  
Q-PCR Assay for Average Telomere Measurement  
Genomic DNA was isolated from 1x 106 cells using GenElute™ Mammalian Genomic DNA 
Miniprep (Sigma), according to manufacturer’s protocol. Average telomere length was measured 
from total genomic DNA by using the qPCR method previously described [53]. Briefly, Q-PCR was 
performed using 35 ng of genomic DNA, 0.25µM of reverse and forward primers and GoTaq® qPCR 
Master Mix (Promega). Primers for telomeric repeats (T) and 36B4, Alu, 18S references (R) were as 
published in [54]. The relative average telomere length was termed the T/R ratio calculated using the 
2-ΔΔCt method. 
Centromere-calibrated Quantitative FISH (Q-FISH)  
Centromere-calibrated Q-FISH staining was performed as described previously [55] with minor 
modifications. Briefly, 48 h after seeding, slides were rinsed with phosphate-buffered saline (PBS), 
pH 7.5, and fixed in 4% formaldehyde for 2 min. After two rinses in PBS, the slides were incubated 
in acidified pepsin solution for 10 min, rinsed and dehydrated through graded alcohols. Slides and 
probes (Cy3 linked telomeric and chromosome 2 centromeric PNA probe, DAKO Cytomatation, 
Denmark) were co-denatured at 80°C for 3 min and hybridized for 2 h at room temperature in a 
humidified chamber. After hybridization, slides were washed twice for 15 min in 70% formamide, 
10 mM Tris, pH 7.2, and 0.1% BSA followed by three 5-min washes in 0.1 M Tris, pH 7.5, 
0.15MNaCl and 0.08%Tween 20. Slides were then dehydrated with an ethanol series and air dried. 
Finally, slides were counterstained with 4,6-diamidino-2 phenylindole (DAPI, Sigma Aldrich, St. 
Louis, MO) in Vectashield (Vector Laboratories, Burlingame, CA). Images were captured at 633 
magnification with an Axio Imager M1 (Carl Zeiss, Germany) equipped with a CCD camera, and the 
telomere size was analyzed with ISIS software (MetaSystems, Germany). The software calculates 
telomere lengths as the ratio between the fluorescence of each telomere signal and the fluorescence 
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of the centromere of chromosome 2, used as the internal reference in each metaphase analyzed. Data 
were expressed as a percentage (T/C%) [56]. 
Telomerase Repeated Amplification Protocol (TRAP) 
TRAP assay was performed as previously described  [57] with minor changes. Briefly, 3x105 cells 
were lysed on ice for 30 minutes in  300µl of NP-40 lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM 
MgCl2 , 1 mM EDTA , 1% v/v NP-40, 0.25 mM Sodium deoxycholate, 10% v/v Glycerol, 150 mM 
NaCl, 5 mM 2-mercaptoethanol, protease inhibitor cocktail Sigma, RiboSafe RNase Inhibitor 
Bioline).  Different serial dilutions of cellular lysates were added to TRAP mix, containing TRAP 
buffer 1x (20mM Tris-HCl pH 8.3, 1.5mM MgCl2, 6.3mM KCl, 0.05% v/v Tween 20, 1mM EGTA), 
0.2mM dNTPs, 4µG BSA, 100ng ACX primer, 100ng NT primer, 100 ng TS primer and 0.01 attomol 
of the internal control TSNT, in a final volume or 50µl. Ten µl of each sample was incubated at 85°C 
for 10 minutes to inactivate telomerase. Heat-inactivated samples were included in the TRAP assay 
as a negative control. Telomerase extension was next performed at 25°C for 40 minutes. PCR 
amplification of extension product was performed following addition of 1.25units of Taq DNA 
Polymerase (New England Biolabs) to TRAP samples. Products were resolved on 10% TBE 
polyacrylamide gels and visualized by staining with Ethidium Bromide using Chemidoc Imaging 
System (Biorad).  Intensity of the telomerase products (6 bp-ladder) was determined by  ImageLab 
Software (Biorad) and normalized with the intensity of  the Internal Control (IC). 
Plasmid and Lentiviral transduction 
FLAG/HA AGO2 coding sequence was PCR-amplified from VP5- FLAG/HA AGO2 plasmid (a kind 
gift from Dr. G. Meister) with primers that introduce BamHI restriction sites at 5’end and SalI 
restriction site at 3’end of the sequence. TERC coding sequence was PCR-amplified from HeLaS3 
genomic DNA with primers that introduce BamHI restriction sites at 5’end and SalI restriction site at 
3’end of the sequence. PCR products were digested with BamHI and SalI and cloned in the lentiviral 
plasmid pLenti CMV GFP Puro (658-5) (a gift from Eric Campeau (Addgene plasmid # 17448) [58]), 
in order to replace GFP open reading frame and originate pLenti CMV FH AGO2 and pLenti CMV 
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TERC wt lentiviral plasmids. Viral particles were obtained by co-transfection of 293T-cells with 
lentiviral plasmids and the PLP-1, PLP-2 and PLP-VSVG plasmids (Invitrogen) and concentrated by 
ultra-centrifugation. HeLaS3 and/or AGO2KO cells were transduced and selected with puromycin. 
TERC mutagenesis 
Terc-sRNA binding site spanning positions 313-340 of TERC (GTCAGCCGCGGGTCTCTCGGG 
GGCG), was mutated in AGACTGGCCCGGCTGTCACCGCGCCC (mutated nucleotides are 
underlined), using Q5 Site-Directed Mutagenesis Kit (NEB) following manufacturer’s protocol. 
Primers for mutagenesis were as follows: Fw TGTCACCGCGCCCAGGGCGAGGTTCAGGCCTT, 
Rev GCCGGGCCAGTCTGAGCCCAACTCTTCGCGGTG. Terc-sRNA binding site spanning 
positions 12-31 of TERC (GGTGGGCCTGGGAGGGGTGG) was deleted, using Q5 Site-Directed 
Mutagenesis Kit (NEB) following manufacturer’s protocol. Primers for mutagenesis were as follows: 
Fw  GGCCATTTTTTGTCTAACCCTAACTGAGAAGG, Rev CTCCGCAACCCGGTGGCG. 
Mutations were verified by Sanger sequencing.  
RNA Immunoprecipitation (RIP) 
For RNA immunoprecipitation from whole-cell extract, 60x106 of cells were lysed in 3 ml of IP-
buffer (150 mM KCl; 25 mM NaCl; 2 mM EDTA; 0.5% NP40; 0,05% Sodium deoxycholate; 0.5 
mM DTT; protease inhibitor (Sigma); RiboSafe RNase Inhibitor (Bioline)) for 20 min on ice. Lysate 
was clarified by centrifugation at 16,000 g for 10 min at 4°C.  
Anti-AGO2 (abcam), anti-AGO1 (N-terminal, Sigma), anti-HA (Sigma) and anti-TERT (C-12, 
Santacruz) antibodies as well as isotype-matched immunoglobulin were coupled to Protein G-
sepharose beads in IP-buffer containing 1 mg/ml heparin (Sigma). Whole-cell lysate was incubated 
overnight at 4°C with antibodies-coupled beads. IP was washed once with IP-buffer and three times 
with IP-wash buffer (50 mM Tris-HCl, pH 7.5; 300 mM NaCl; 5 mM MgCl2; and 0.05% Nonidet P-
40). An aliquot of IP was saved for western blot analysis. TriFast  (0.6 ml) (Euroclone) was added to 
the rest of each IP sample. 
RNA isolation and qRT-PCR
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Total RNA as well as RIP samples were isolated using Direct-zol™ RNA MiniPrep Kit (Zymo 
Research) according to manufacturer’s protocol. Reverse transcription was performed from 200 ng 
of total RNA or 1/10 of RIP samples, using GoScriptTM Reverse Transcriptase (Promega), following 
manufacturer’s protocol. Random primers (Promega) or oligo(dT)15 were used for total RNA or 
polyadenylated RNA reverse transcription, respectively. qPCR was performed with GoTaq® qPCR 
Master Mix (Promega) and primers were as follows: TERC Fw GCGAAGAGTTGGGCTCTGTCA, 
Rev TTCCTCTTCCTGCGGCCTGAAA; 3’ extended TERC Fw 
CTTTCAGGCCGCAGGAAGAGGAA, Rev GGTGACGGATGCGCACGAT; HPRT1 Fw 
CAAAGATGGTCAAGGTCGC, Rev TCAAATCCAACAAAGTCTGGC; HOTAIR Fw 
GGTAGAAAAAGCAACCACGAAGC, Rev ACATAAACCTCTGTCTGTGAGTGCC; 7SK Fw 
CCCCTGCTAGAACCTCCAAAC, Rev CACATGCAGCGCCTCATTT. EctoTERC was amplified 
by using a Fw primer mapping inside TERC coding sequence (AAGAGGAACGGAGCGAGTC) and 
a Rev primer mapping on the specific sequence at the 3’end of ectoTERC 
(GCATGTGTGAGCCGAGTC). 
Target enrichment in IP sample was normalized using 7SK RNA enrichment, as an unrelated RNA 
[59], and calculated using the 2-ΔΔCt method. 
sRNA isolation and qRT-PCR 
sRNA fraction (<100nt) was isolated by miRNA Isolation Kit (Genaid), accordingly to 
manufacturer’s protocol. sRNA isolation was verified on a 2% agarose gel, where transfer-RNA was 
loaded as molecular weight reference. terc-sRNA expression was checked by using Custom 
TaqMan® Small RNA Assay (Thermo Fisher Scientific). One hundred ng of sRNAs or 1/10 of RIP 
samples was reverse transcribed using SuperScript II Reverse Transcriptase (Thermo Fisher 
Scientific) and qPCR was performed using iTaq Universal Probes Supermix (Biorad). Quantification 
was normalized to small nucleolar RNA U44, amplified by TaqMan® Small RNA Assay (Thermo 
Fisher Scientific).  
Protein Isolation and Western blot 
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For whole-cell protein extracts, cells were lysed in RIPA Buffer (150mM NaCl, 1% NP-40, 0.5% 
Sodium deoxycholate, 0.1% SDS, 50mM Tris pH 8, 1mM DTT, protein inhibitor cocktail).  
For Western blot analyses the following antibodies were used: anti-AGO2 (11A9, Millipore), anti-
AGO1 (N-terminal, Sigma), anti-HA (F-7, Santacruz), anti-TERT (H-231, Santacruz), anti-GAPDH 
(14C10, Cell Signaling technology), GW182 ( A302-329A, Bethyl Laboratories). 
Microarray analysis  
Total RNA from parental or AGO2KO HeLaS3 cells was isolated by TRI Reagent (Sigma), following 
manufacturer’s protocol. Microarray was performed by The Genomics Core Facility (GeneCore) at 
EMBL (Heidelberg, Germany). GeneChip™ Human Gene 2.0 ST Array (Affymetrix) was used. 
Microarray data were analysed using R Bioconductor. Package “oligo” was used to import .cel files; 
library “hugene20sttranscriptcluster.db” was used for gene annotation; package “genefilter” was used 
for filtering; package “limma” was used for data analysis.  
sRNA Seq analysis  
Adapter sequences were removed using cutadapt[ref]. Reads were first aligned to human mirna 
hairpin sequences (mirBase 21). Unaligned reads were then aligned on human rRNA and tRNA 
database. Fianlly, all unaligned reads were aligned on hg38 human genome reference. All alignements 
were performed with bowtie1, using the following parameters: -n 2 -l 18. In the last alignement round 
only sequences with a single valid alignement were taken into account (option -m 1). Coverage plots 
were obtained using bedtools genomeCoverage. 
RNA-hybrid analysis 
Target sequences of terc-sRNA were identified using RNAhybrid 2.1.2 [27] using the option -s 
3utr_human. 
Data Avaibility 
The datasets analyzed during the current study are available in the ENA repository (ERX350060, 
ERX338767, ERX344794, ERX344797), in the SRA repository (SRP022054, SRP028291, 
SRP014142, SRP045645, SRP003902, SRP048750) and in ArrayExpress (E-MTAB-7085). 
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Figure legends 
Figure 1. AGO2 depletion in human cells reduces proliferation rate in vitro and tumor growth 
in vivo.  
A. Proliferation curves of parental and AGO2KO HeLaS3 cells are plotted (n=6 experimental 
replicates).  
B. Colony-forming activity of HeLaS3 and AGO2KO cells was determined by colony-formation 
assay (n=3 experimental replicates).  
C. Tumour growth curves of xenografts derived from HeLaS3 or AGO2KO cells are shown as tumour 
diameter at different time points (n=5 mice for each group).  
D. Xenograft tumour weights were measured 30 days post- injection (n=5 mice for each group).  
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.01 (Student’s 
t-test) 
Figure 2. AGO2 interacts with a sRNA arising from TERC locus (terc-sRNA)  
A. TERC RNA secondary structure (adapted from http://telomerase.asu.edu). Terc- sRNA is 
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highlighted in purple  
B. HeLaS3 cells were transduced with a lentiviral vector coding for human TERC (HeLaS3_TERC) 
or for GFP, as a control (HeLaS3_GFP). The relative expression of TERC was measured by RT–
qPCR. HPRT1 was used as internal control (n = 3 experimental replicates). 
C. The relative expression of terc-sRNA was measured in HeLaS3_TERC and HeLaS3_GFP by RT–
qPCR. RNU44 was used as internal control (n = 3 experimental replicates). 
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; ***P≤ 0.01 (Student’s t-test). 
Figure 3. AGO2 controls telomere length and telomerase activity.  
A. Average telomere length was measured from genomic DNA of parental and AGO2KO HeLaS3, 
by qPCR amplification of telomere repeats (T) and multicopy gene Alu (R), as a reference. The 
relative telomere length (T/R) was plotted (n=3 experimental replicates)  
B. Representative images of metaphase spreads obtained from HeLaS3 and AGO2KO cells stained 
for telomeric sequences and centromere 2 alphoid DNA.  
C. Representative telomere length distributions in parental and AGO2KO HeLaS3. Average telomere 
length and the standard deviation, as well as the total number of telomeres analyzed, are indicated. 
Notice the marked shift towards short telomeres in AGO2KO cells compared with the parental HeLa 
S3 cell line. 
D, E. Telomerase activity was detected by TRAP in parental HeLaS3 and AGO2KO cells. 293T cells 
were used as a positive control. As negative controls, telomerase was heat- inactivated in cell extracts, 
in the last lane no cells were added in lysis buffer. Intensity of the telomerase products (6 bp-ladder) 
was determined by ImageLab Software (Biorad) and normalized with the intensity of the Internal 
Control (IC) (n=3 experimental replicates). 
F. AGO2KO cells were transduced with a lentiviral vector coding for FLAG-HA-tagged AGO2 
(AGO2KO_FH AGO2) or for GFP as a control (AGO2KO_GFP). Quantification of telomerase 
activity in AGO2KO_FH AGO2 and AGO2KO_GFP, as assessed by TRAP, was plotted (n=3 
experimental replicates). 
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G. HeLaS3 cells were transduced with a lentiviral vector coding for FLAG-HA-tagged AGO2 
(HeLaS3_FH AGO2) or for GFP as a control (HeLaS3_GFP). Quantification of telomerase activity 
in HeLaS3_FH AGO2 and HeLaS3_GFP, as assessed by TRAP, was plotted (n=3 experimental 
replicates). 
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.01 (Student’s 
t-test) 
Figure 4. AGO2 expression does not affect neither TERC RNA levels and 3’-end processing nor 
TERT protein abundance, but controls association between TERT and TERC.  
A. The relative expression of TERC was measured by RT–qPCR from total RNA of HeLaS3 and 
AGO2KO cells. HPRT1 was used as internal control (n = 3 experimental replicates). 
B. qPCR of 3’-extended TERC transcript in cDNA from HeLaS3 and AGO2KO cells generated using 
random hexamers. HPRT1 was used for normalization (n=3 experimental replicates). 
C. qPCR of TERC transcript in cDNA from HeLaS3 and AGO2KO cells generated using oligo(dT)10 
priming. HPRT1 was used for normalization (n=3 experimental replicates). 
D. Whole cell extract of HeLaS3 and AGO2KO was analyzed by western blot for the presence of 
TERT protein. GAPDH was used as loading control. Data are representative of 4 independent 
experiments. 
E. TERT protein level was quantified by ImageLab Software (Biorad). GAPDH was use as internal 
control (n=4 experimental replicates)  
F-G. HeLaS3 and AGO2KO cell extracts (n=3), as well as AGO2KO_FH AGO2 and AGO2KO_GFP 
cell extracts (n=3 experimental replicates) were immunoprecipitated using an anti-TERT antibody or 
IgG as mock IP. TERC and HOTAIR (as a negative control) abundance was assessed by RT-qPCR. 
HPRT1 was used for normalization and enrichment in TERT-RIP as compared to IgG RIP was 
plotted.  
H. HeLaS3 whole-cell extract was immunoprecipitated using anti- AGO2 antibody or IgG, as mock 
IP. Whole cell lysates (input) and immunoprecipitates were analyzed by western blot with anti-TERT 
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antibody. As a positive control, the presence in immunoprecipitates of GW182, a known AGO2-
interacting protein, was assessed. Data are representative of three independent experiments. 
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; ns= not significant (Student’s t-test) 
Figure 5. AGO2 is bound to TERC RNA and deletion of TERC regions complementary to terc-
sRNA impairs AGO2/TERC interaction.   
A. HeLaS3 whole-cell extract was immunoprecipitated using anti- AGO2 antibody or IgG, as mock 
IP. TERC RNA enrichment in AGO2 RIP as compared to IgG RIP was assessed by RT-qPCR . 7SK 
RNA was used for normalization (n=4 experimental replicates). 
B. RIP assay was performed from HeLaS3_FH AGO2 and HeLaS3_GFP cell extract using anti-HA 
antibody or IgG, as negative control, followed by TERC detection by RT-qPCR. 7SK RNA was used 
for normalization (n=3 experimental replicates). 
C. HeLaS3 cells were transduced with a lentiviral vector coding for wild-type TERC 
(HeLaS3_TERCwt), TERC mutated in position 313-340 (HeLaS3_TERC (313-340mut)) or TERC 
delated in position 12-31 (HeLaS3_TERC (Δ 12-31)). Whole-cell lysates from HeLaS3_TERCwt, 
HeLaS3_TERC(313-340mut) and HeLaS3_TERC (Δ 12-31) was immunoprecipitated using an anti-
AGO2 antibody in order to assessed the impact of TERC mutations on AGO2 binding. For each 
experiment the enrichment of ectoTERC as compared to 7SK RNA in RIP samples was normalized 
on the amount of ectoTERC and 7SK RNA in input samples. Association of AGO2 with TERC(313-
340mut and TERC (Δ 12-31) was compared to the association with TERCwt (n=3 experimental 
replicates).  
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.01 (Student’s 
t-test) 
Figure 6. Terc-sRNA overexpression increases telomerase activity even in the absence of AGO2. 
A-B. HeLaS3 and AGO2KO cells were transfected with a synthetic terc-sRNA or an siRNA with no 
target in humans (siCtl), as a control. Four days after transfection, telomerase activity in 100- and 50 
cell-lysate was assessed by TRAP. Intensity of the telomerase products (6 bp-ladder) was determined 
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by ImageLab Software (Biorad) and normalized with the intensity of the Internal Control (IC), (n=4 
experimental replicates) 
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; **P≤ 0.01 (Student’s t-test) 
 
Expanded View Figure Legend 
Fig EV1. The newly identified AGO2-bound terc-sRNA is processed in a DICER- and AGO2-
independent manner.  
A. Coverage of a sRNA (23 nt) arising from positions 425 to 447 of mature TERC RNA (terc- sRNA), 
as assessed by sRNA-Seq of nuclear AGO2-IP from HCT116 and HeLaS3 cells.  
B. Validation of sRNA-Seq was performed by immunoprecipitating AGO2-bound RNA from 
HeLaS3 whole-cell extract using a different anti-AGO2 antibody or IgG, as negative control. 
Immunoprecipitation was verified by western blot. 
C. RIP assay was performed from HeLaS3 whole-cell extract using anti- AGO2 antibody or IgG, as 
negative control. Terc-sRNA enrichment in AGO2 RIP as compared to IgG RIP was assessed by RT-
qPCR. 7SK RNA was used for normalization (n=3 experimental replicates).  
D-G. Terc-sRNA, miR-21, miR-30a and let7f abundance was assessed in small RNA (< 100nt) 
fractions of HCT116 and HCT116 DICEREX5 (D, E) and of HeLaS3 and AGO2KO cells (F, G). 
RNU44 was used as internal control (n = 3 experimental replicates). 
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; ns= not significant (Student’s t-
test). 
Fig EV2. AGO1 binds to terc-sRNA and to TERC but AGO1 depletion does not affect 
telomerase activity neither in wild type nor in AGO2KO background. 
A. Coverage of terc-sRNA, as assessed by sRNA-Seq of nuclear AGO1-IP from HeLaS3 cells.  
B. RIP assay was performed from HeLaS3 cell extract using anti- AGO1 antibody or IgG, as negative 
control. Immunoprecipitation was verified by western blot. 
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C-D. TERC RNA (n=3 experimental replicates) and terc-sRNA (n=5 experimental replicates) 
enrichment in AGO1 RIP as compared to IgG RIP was assessed by RT-qPCR. 7SK RNA was used 
for normalization. 
E. Telomerase activity was detected by TRAP in two HeLaS3 clones isolated following transduction 
with LentiCRISPR v2 control vector (HeLaS3 WT CRISP neg), in AGO2KO cells following 
transduction with LentiCRISPR v2 (AGO2KO CRISPR neg), two AGO1/AGO2 double KO clones 
isolated from AGO2KO cells following transduction with LentiAGO1CRISPR v2 
(AGO1/AGO2dKO) and two AGO1 KO clones isolated from HeLaS3 cells following transduction 
with LentiAGO1CRISPR v2 (AGO1KO). Quantitative analysis of telomerase activity was plotted 
(n=3 experimental replicates). 
Data information. Data are expressed as mean ± SEM. *P≤ 0.05; **P≤ 0.01; ns= not significant 
(Student’s t-test). 
Fig EV3. Terc-sRNA is expressed in human primary samples and over-expressed in cancerous 
tissues compared to control tissues 
A. Coverage of terc-sRNA as assessed by sRNA-Seq from different primary tissues.  
B. Terc-sRNA expression (RPM) in different tumor types compared to control tissues. Tumor 
datasets of sRNA-Seq are from SRA repository: SRP028291, SRP014142, SRP048750, SRP045645 
and SRP003902, SRP022054 (Wilcoxon sum-rank test). 
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Appendix figure S1
Gene Symbol Gene Name Linear fold change(AGO2KO/HeLaS3)*
RASEF RAS and EF-hand domain containing 018
LINC00958 long intergenic non-protein coding RNA 958 0.19
ATRN attractin 0.24
ALKBH3 alkB homolog 3, alpha-ketoglutaratedependent dioxygenase 0.26
TMPRSS15 transmembrane protease, serine 15 0.27
CDH13 cadherin 13 0.32
CACHD1 cache domain containing 1 0.36
AGO2 argonaute 2, RISC catalytic component 0.36
BICC1 BicC family RNA binding protein 1 0.42
SLCO1C1 solute carrier organic anion transporter family member 1C1 1.93
SORBS2 sorbin and SH3 domain containing 2 3.45
SRGN serglycin 18.96
*FDR < 0.01 
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Appendix figure S1. A. Data from microarray are graphed on a scatter plot to visualize variations in
gene expression between parental and AGO2KO HeLaS3 cells. Genes attaining statistical significance
(FDR < 0.01) are highlighted in red. B. List of genes differentially expressed in AGO2KO cells as
compared to parental cells, as assessed by microarray.
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Sequence 5’>3’
terc-sRNA UGCACCCAGGACUCGGCUCACA
A
B
Appendix figure S2. A. Terc-sRNA sequence. B. Terc-sRNA was detected by qRT-PCR by a Custom
TaqMan Small RNA Assay (cat. 4398987, Applied biosystems). One fmol of a synthetic double stranded
terc-sRNA was reverse transcribed and qPCR primer efficiency was verified by amplification of 3 ten-fold
serial dilutions of the reverse transcription reaction. C, D, E. Small RNA fraction (< 100 nt) was isolated
from HeLaS3_TERC, HeLaS3_GFP, HeLaS3, AGO2KO, HCT116 and HCT116DICER EX5 . Transfer-RNA
(tRNA) was loaded as molecular weight reference.
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Appendix figure S3
Appendix figure S3. A. Average telomere length was measured from genomic DNA of parental and AGO2KO
HeLaS3, by qPCR amplification of telomere repeats (T) and the multicopy gene 18S or the four-copy gene 36B4 (R),
as references. The relative telomere length (T/R) was plotted (n=3 experimental replicates). Data are expressed as
mean ± SEM. **P≤ 0.01; (Student’s t-test). B. Telomere length per metaphase in HeLa S3 and AGO2KO cell lines.
Box plot represent median, 25th and 75th percentile whereas skewers represent 10th and 90th percentile. Black
circles denote outliers (over 90th percentile and under 10th percentile) (n=22). ***P≤ 0.001; (Student’s t-test). C.
Stacked histograms showing percent of telomeres shorter than 5, 10 and 15 T/C% and longer than 16 T/C% in
parental and AGO2KO HeLaS3 (n=2 experimental replicates). D, E. AGO2KO and HeLaS3 cells were transduced
with a lentiviral vector coding for FLAG-HA-tagged AGO2 (AGO2KO_FH AGO2 and HeLaS3_FH AGO2,
respectively) or for GFP as a control (AGO2KO_GFP and HeLaS3_GFP, respectively). Expression of ectopic
protein was verified by western blot using anti-HA and anti-AGO2 antibodies. GAPDH was used as loading control
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Appendix figure S4. A. HeLaS3 cells were transduced with a lentiviral vector coding for human
TERC (HeLaS3_TERCwt) or for GFP, as a control (HeLaS3_GFP). The relative abundance of
ectopically expressed TERC RNA (ectoTERC) was measured by RT–qPCR using primers which do
not amplify endogenous TERC. HPRT1 was used as internal control (n=3 experimental replicates). B.
RIP assay was performed from HeLaS3_TERCwt whole-cell extract using anti- AGO2 antibody or
IgG, as negative control. EctoTERC enrichment in AGO2- and IgG RIP was assessed by RT-qPCR .
7SK RNA was used for normalization (n=3 experimental replicates). C-D. RNAhybrid prediction of
the best minimum free energy (mfe) duplexes of terc-sRNA and TERC. E. The relative expression of
ectoTERC was measured by RT–qPCR from total RNA of HeLaS3_TERCwt, HeLaS3_TERC (313-
340mut) and HeLaS3_TERC (Δ 12-31) cells. 7SK RNA was used as internal control (n=3
experimental replicates).
HeLaS3_TERCwt
mfe: -24.9 kcal/mol
p-value: 0.444469
mfe: -30.0 kcal/mol
p-value: 0.049934
TERC  313-340  5' C   C     CG    U  C   G   A 3'
UGU AGCCG  GGUC CU GGG GCG   
||| |||||  |||| || ||| |||
ACA UCGGC  UCAG GA CCC CGU   
terc-sRNA  3' C   C                  A     5'
TERC  380-403 5'    G           CCGCGC C  C   A 3'
GAG CGAGUCC      G GG GCG  
||| |||||||      | || |||  
CUC GCUCAGG      C CC CGU    
terc-sRNA 3' CACA   G       A         A        5'
mfe: -29.4 kcal/mol
p-value: 0.065980
TERC 12-31 5'  G       U   AG       G  3'
GUGGGCC GGG    GGGUG    
||||||| |||   |||||
CACUCGG CUC    CCCAC     
terc-sRNA 3' CA           AGGA     GU 5'
mfe: -24.9 kcal/mol
p-value: 0.444469
mfe: -30.0 kcal/mol
p-value: 0.049934
TERC  313-340  5' C   C     CG    U  C   G   A 3'
UGU AGCCG  GGUC CU GGG GCG   
||| |||||  |||| || ||| |||
ACA UCGGC  UCAG GA CCC CGU   
terc-sRNA  3' C   C                  A     5'
TERC  380-403 5'    G           CCGCGC C  C   A 3'
GAG CGAGUCC      G GG GCG  
||| |||||||      | || |||  
CUC GCUCAGG      C CC CGU    
terc-sRNA 3' CACA   G       A         A        5'
mfe: -29.4 kcal/mol
p-value: 0.065980
TERC 12-31 5'  G       U   AG       G  3'
GUGGGCC GGG    GGGUG    
||||||| |||   |||||
CACUCGG CUC    CCCAC     
terc-sRNA 3' CA           AGGA     GU 5'
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Appendix figure S5. Coverage of sRNA mapping on TERC gene from nuclear AGO2-RIP 
experiment in HCT116, HCT116 (DICER EX5), and HelaS3 and from nuclear AGO1-RIP in HelaS3. 
TERC RNA is transcribed from the - strand of DNA. Reads mapping to the - strand (sense orientation 
with respect to TERC transcription) are plotted in blue, whereas reads mapping to the + strand (anti-
sense orientation with respect to TERC transcription) are plotted in red.
Appendix figure S5
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Appendix figure S6
Appendix figure S6. A. CRISPR/Cas9 technology was used to generate AGO1KO and AGO1/AGO2dKO
cell lines. Expression of AGO1 and AGO2 was verified by western blot in two HeLaS3 clones isolated
following transduction with CRISPR/Cas9 control lentiviral vector (HeLaS3 WT CRISPR neg cl9 and cl10),
in AGO2KO cells following transduction with CRISPR/Cas9 control vector (AGO2KO CRISPR neg), in two
AGO1 KO clones isolated from HeLaS3 cells following transduction with AGO1-targeting CRISPR/Cas9
vector (AGO1KO cl5 and cl11) and in two AGO1/AGO2 double KO clones isolated from AGO2KO cells
following transduction with AGO1-targeting CRISPR/Cas9 vector (AGO1/AGO2dKO cl3 and cl7). GAPDH
was used as loading control. B. Telomerase activity was detected by TRAP in the indicated cell lines. Data
are representative of three independent experiments. IC= internal control
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